Since its introduction, the PABA test has gained an established position in the battery of tests available for the diagnosis of exocrine pancreatic insufficiency.' Advantages of the test are the fact that no invasive procedures are necessary and that simple colorimetric procedures are available for the quantification of p-aminobenzoic acid (PABA) in urine. ' .
It shares, however, a lack of specificity with other non-invasive and indirect pancreatic function tests.' Falsely low excretion rates can be obtained by defects in gastric emptying, in endogenous stimulation of the pancreas, failure in raising the intestinal pH, abnormalities in intestinal PABA resorption, in liver function and in renal excretion.
For a screening test to be used in a patient population with a low prevalence of the disease, a high specificity is of the utmost importance to obtain an acceptable predictive value of a positive result. Administration of an equimolar dose of free PABA on a separate occasion and calculation of a PABA excretion index has been recommended to compensate for abnormalities in PABA resorption and metabolism. In five healthy volunteers PAS excretion was measured once together with BTPABA and once with free PABA. Excretions measured were 74.7 and 73.3%, 65-7 and 52.7%, 54-5 and 59.0%, 79-7 and 73.0%, 70-1 and 69*8% respectively. Calculation of the PABA excretion index was also possible for these persons. Results for the PABA excretion index and the PABA/PAS ratio for these five volunteers are given in the Table. Based on the results in the 21 normal controls 0.75 was arbitrarily accepted as lower limit of normal for the PABA/PAS ratio. The lower limit of normal for PABA excretion was 50%. The results for the normal controls and the patients are given in Figure 2 , expressed as per cent PABA recovered and as PABA/PAS ratio. In 25 of the 38 patients with pancreatic disease the PABA/PAS ratio was abnormal, giving a sensitivity of 66%, while PABA excretion was <50% in 28 patients (74%). In the group of patients without pancreatic disease and the controls the PABA/PAS ratio was abnormal in seven of 63 cases, resulting in a specificity of 89%, compared with an abnormal PABA excretion in 15 of the 63 cases (specificity 76%). Results of the PABA/PAS The excretion index described by us here also has the advantage that it takes only a single six hour urine collection, but in addition it puts no restrictions on the patients to be investigated. For a reliable calculation of a PABA excretion index it is essential that the pharmacokinetic properties of the marker resemble the kinetics of PABA metabolism and excretion as closely as possible. Therefore we started to look for compounds with a molecular structure strongly related to PABA. PAS was chosen for the following reasons: (1) PAS differs from PABA only by one hydroxy-group. (2) In the literature data were available to prove its comparable metabolism'`and its high urinary excretion rate,'4 supported later by our data reported here (Fig. 1). (3) PAS has been in use as a tuberculostatic drug for a long time in the recent past and much higher doses than used in this study have been administered safely to patients. Therefore we could be sure that no side effects were to be expected with the dose used in this study. This obviated the necessity of prior toxicologic studies. (4) In our HPLC assay for PABA,' PAS was detected also with a retention time suitable for accurate quantification of both compounds. As reported here for five healthy volunteers day to day variations in PAS excretion were not always negligible, confirming the day to day variations in PABA excretion reported by Kay et al. 2 As a consequence, in one case a difference of 0-22 was found between PABA/PAS ratio and PABA excretion index (Table) , although in the other case both parameters corresponded very well.
It may be pointed out here that small differences in excretion rate between the chosen marker and released PABA will not decrease the value of the excretion index. Also free PABA resorption and excretion are not completely parallel to the resorption and excretion of PABA, that has to be split off first from BTPABA in the duodenum. In healthy controls it was shown that with free PABA there was a smaller lag between oral ingestion and urinary excretion, even when taken with a meal" (Fig. 1) . The difference may probably be explained by differences in gastric emptying of on the one hand free PABA, which is readily soluble at the low pH of the gastric contents, and on the other hand BTPABA, which is virtually insoluble at pH<5. For PAS, also acid soluble, only a slightly lower excretion rate was observed than for free PABA (Fig. 1) and PAS excretion differed therefore to the same extent as free PABA did from the excretion of PABA produced by BTPABA proteolysis in vivo.
The optimal dose of BTPABA is probably determined by the limited capacity of the body for handling PABA. 
